2025年WCLC摘要公布！100%纯度的港股通创新药ETF(159570)连续回调跌超2%，资金持续暴力流入！机构：创新药大跌正适合回调加仓！

Group 1 - The Hong Kong stock market experienced a collective adjustment, with the Hong Kong Stock Connect Innovative Drug ETF (159570) seeing a significant decline for three consecutive days, dropping over 2% during intraday trading, and achieving a transaction volume exceeding 3.3 billion HKD, with over 43 million HKD raised in a single day [1] - The Innovative Drug ETF (159570) has recorded a net inflow of funds for 28 consecutive days, accumulating over 7.1 billion HKD in the last 20 days, indicating strong investor interest [1] - As of August 26, the latest scale of the Innovative Drug ETF (159570) exceeded 18.9 billion HKD, maintaining a leading position in terms of scale and liquidity [1] Group 2 - Major component stocks of the ETF, including Kangfang Biotech and China Biopharmaceutical, experienced declines of over 3% and 2.5% respectively, reflecting a broader downturn in the sector [2][5] - Kangfang Biotech successfully raised 3.52 billion HKD through the placement of new shares and existing shares to advance the development of innovative antibody drugs, focusing on proprietary intellectual property [2] - The World Lung Cancer Conference (WCLC) is scheduled for September 6-9, 2025, in Barcelona, where Chinese pharmaceutical companies will showcase innovative research results, highlighting the growing importance of domestic innovation in the pharmaceutical sector [3] Group 3 - Recent data from the WCLC indicates that Kangfang Biotech will present clinical research data for its drug AK112, while other companies like Hengrui Medicine and Legend Biotech will also report their clinical findings, showcasing the competitive landscape of innovative drug development [3] - A report from Ping An Securities highlights the emergence of PD-1/VEGF dual antibodies as a significant area of focus, with several companies, including BioNTech and Kangfang Biotech, advancing their clinical trials in this space [4][6] - The Innovative Drug ETF (159570) has shown a remarkable increase of over 109% within the year, outperforming other indices in the healthcare sector, indicating strong market performance and investor confidence in innovative drug companies [7][8]